Idelvion Purple Book BLA 125582

BLA number
125582
Proprietary names
Idelvion
Proper names
Coagulation Factor IX (Recombinant), Albumin Fusion Protein
Applicant
CSL Behring Lengnau AG
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001IdelvionCoagulation Factor IX (Recombinant), Albumin Fusion Protein351(a)500IUFor InjectionIntravenousSingle-Dose VialRxLicensed2016-03-04
002IdelvionCoagulation Factor IX (Recombinant), Albumin Fusion Protein351(a)1000IUFor InjectionIntravenousSingle-Dose VialRxLicensed2016-03-04
003IdelvionCoagulation Factor IX (Recombinant), Albumin Fusion Protein351(a)2000IUFor InjectionIntravenousSingle-Dose VialRxLicensed2016-03-04
004IdelvionCoagulation Factor IX (Recombinant), Albumin Fusion Protein351(a)250IUFor InjectionIntravenousSingle-Dose VialRxLicensed2016-03-04
005IdelvionCoagulation Factor IX (Recombinant), Albumin Fusion Protein351(a)3500IUFor InjectionIntravenousSingle-Dose VialRxLicensed2018-05-30

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2021-09-01U001Idelvion351(a)RxCSL Behring Lengnau AG
2021-09-01U002Idelvion351(a)RxCSL Behring Lengnau AG
2021-09-01U003Idelvion351(a)RxCSL Behring Lengnau AG
2021-09-01U004Idelvion351(a)RxCSL Behring Lengnau AG
2021-09-01U005Idelvion351(a)RxCSL Behring Lengnau AG
2021-05-01U001Idelvion351(a)RxCSL Behring Lengnau AG
2021-05-01U002Idelvion351(a)RxCSL Behring Lengnau AG
2021-05-01U003Idelvion351(a)RxCSL Behring Lengnau AG
2021-05-01U004Idelvion351(a)RxCSL Behring Lengnau AG
2021-05-01U005Idelvion351(a)RxCSL Behring Lengnau AG
2020-08-01R001Idelvion351(a)RxCSL Behring Lengnau AG
2020-08-01R002Idelvion351(a)RxCSL Behring Lengnau AG
2020-08-01R003Idelvion351(a)RxCSL Behring Lengnau AG
2020-08-01R004Idelvion351(a)RxCSL Behring Lengnau AG
2020-08-01R005Idelvion351(a)RxCSL Behring Lengnau AG

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-08-01001Idelvion351(a)RxLicensed2016-03-04
2020-08-01002Idelvion351(a)RxLicensed2016-03-04
2020-08-01003Idelvion351(a)RxLicensed2016-03-04
2020-08-01004Idelvion351(a)RxLicensed2016-03-04
2020-08-01005Idelvion351(a)RxLicensed2018-05-30